Skip to content
Thu 19 Nov 2026 Toronto Sign in
Health Tech

FDA Cleared an App That Doses Insulin Without a Doctor. Where’s the Data?

DreaMed's MODI tells adults with type 2 diabetes how to change their insulin doses from CGM readings. Three weeks after clearance, its trial is still enrolling and no results are public.

Illustration: a phone showing a glucose trend line settling into a single dose marker.
Illustration: prompt/power

Updated Oct. 19, 2026: We rebuilt this story on DreaMed’s own release and the public trial registry. As of Oct. 19, DreaMed has published no trial results for MODI, we could not confirm a public FDA decision summary for the clearance, and the one MODI study we found on ClinicalTrials.gov, a 102-person safety trial, is listed as still enrolling.

An app can now tell some people with type 2 diabetes how much insulin to inject, and no doctor has to sign off on the number. On Sept. 28, Israeli software company DreaMed Diabetes announced that the US Food and Drug Administration had granted 510(k) clearance to MODI, a mobile app that reads continuous glucose monitor (CGM) data and insulin data and recommends dose changes directly to the patient. It is cleared for adults 18 and older who inject long-acting insulin, with or without rapid-acting insulin at meals. DreaMed has not said when MODI will launch, what it will cost or which clinical results persuaded the FDA.

That last gap is the story. The clearance is real. The evidence behind it is not yet something a patient, a clinician or a reporter can read.

What the FDA cleared, according to DreaMed

DreaMed’s release makes two claims that set MODI apart from the dosing calculators already on the market. The app recommends insulin dose adjustments directly to patients and does not require a healthcare provider to review or approve each adjustment. Providers also do not have to configure the starting insulin settings. In the company’s telling, the app turns CGM patterns and insulin data into a dosing recommendation, and the patient acts on it.

The company calls MODI “the first FDA-cleared solution” to use glucose-monitoring data to automatically optimize insulin dosing in type 2 diabetes across both basal-only and multiple-daily-injection regimens, and says the clearance “opens a major new category in insulin care.” Automated dosing so far has mostly been built for people with type 1 diabetes who wear insulin pumps, the release notes. MODI moves the idea to people who inject, where there is no pump to do the delivering.

The market DreaMed is pitching is large. Its release says injection users make up 85% of insulin users, citing the American Diabetes Association, that more than eight million people in the US inject insulin, and that most of them sit above recommended glucose targets while going months between dose changes.

“Today we can track glucose continuously, but insulin treatment is still only adjusted months apart,” Eran Atlas, DreaMed’s co-founder and chief executive, said in the release. He added that “data alone does not improve the health of patients.”

MODI at a glance: cleared, claimed and still unpublished

Question What the public record shows Source
What MODI does Uses CGM and insulin data to recommend insulin dose adjustments directly to the patient through a mobile app DreaMed release, Sept. 28
Clinician role No provider review or approval of each adjustment; no provider setup of initial insulin settings DreaMed release
Who it’s cleared for Adults 18+ with type 2 diabetes on injectable long-acting insulin, with or without rapid-acting insulin (basal-only and MDI) DreaMed release
Regulatory pathway 510(k) clearance; the release gives no 510(k) number DreaMed release
Supporting trial data Not published as of Oct. 19 Our search of DreaMed’s site and ClinicalTrials.gov
Registered MODI trial NCT07599982, single-arm, 13 weeks, estimated 102 adults, listed as enrolling; no results posted ClinicalTrials.gov
Price, launch date, partners Not stated DreaMed release

No clinician in the loop, by design

Much of the regulatory argument over medical AI has been about software that advises clinicians, who then decide. The FDA’s guidance on clinical decision support software was revised in January 2026, a change law firms including Covington summarized at the time. MODI doesn’t live in that world. It speaks to the patient, and DreaMed took it through 510(k) clearance as a medical device.

That choice cuts both ways. A device clearance means the FDA reviewed the product rather than letting it ship as clinician-facing advice. It also means the safety case rests on whatever DreaMed submitted, and the public can’t yet see it.

DreaMed is not new to this. Trade publication FDAnews has reported earlier clearances, under headlines such as “DreaMed’s insulin dosing software earns clearances” and “DreaMed gets additional FDA clearance for diabetes analyzer.” The release describes more than a decade of clinical, algorithmic and regulatory work and an existing platform, endo.digital, that serves healthcare providers. MODI is the first product it describes as going straight to the person doing the injecting.

The MODI trial on the registry is still enrolling

The only MODI study we found on ClinicalTrials.gov is NCT07599982, titled “Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes,” with the acronym MODIUS. The registry’s main site renders as a script-only shell, so we read the record’s details from a public mirror of the listing. It shows:

  • Sponsor: DreaMed Diabetes. Status: enrolling.
  • Design: open-label, single group, no control arm. The summary describes “a 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase.”
  • Size: an estimated 102 participants at six sites.
  • Who: adults 18 to 80 with diabetes for at least six months and an HbA1c above 7.5% and below 12%. That includes people with type 1 diabetes on multiple daily injections, and people with type 2 diabetes on multiple daily injections, on basal insulin alone, or about to start basal insulin.
  • Results: none posted. The mirror lists no start, completion or outcome-measure details.

Two things stand out. The study includes people with type 1 diabetes, a group MODI is not cleared to treat. And a trial that is still recruiting cannot be the published evidence for a clearance granted on Sept. 28. Our read: MODIUS looks like groundwork for a broader label, while whatever supported the type 2 clearance sits in DreaMed’s FDA file. We can’t confirm that from the public record, and DreaMed’s release does not say.

What’s still missing from the public record

The FDA keeps a public 510(k) database at accessdata.fda.gov. As of Oct. 19, we could not confirm a MODI entry or decision summary there, and the release gives no clearance number to search by. Until one appears, these questions have no public answer:

  • How MODI performed against usual care, and in how many patients.
  • How it handles hypoglycemia, missed doses or a CGM that stops reporting.
  • Which CGMs and insulins it works with.
  • What the cleared indications for use say, word for word.

None of this means MODI is unsafe. It means the evidence for an app that changes an insulin dose without a clinician’s approval is, for now, a company’s description of an FDA decision.

Autonomy is arriving elsewhere in medicine, too. In England, an AI skin cancer tool can now discharge patients without a dermatologist, and Utah is letting an AI write a first acne prescription. More in our policy coverage.

What it means for patients and clinicians

  • If you inject insulin for type 2 diabetes: MODI is not something you can download today on the strength of the release. DreaMed has given no launch date or price. Ask your clinician before changing how you adjust doses.
  • If you prescribe insulin: the release says you won’t set MODI’s starting doses or approve its changes. Before recommending it, ask DreaMed for the FDA indications for use and the clinical data in its submission.
  • If you’re watching the policy: the next documents to read are the FDA’s 510(k) summary, once posted, and any results from NCT07599982.

DreaMed’s own pitch is that insulin doses get changed only every few months. MODI would change them as often as the data says. What nobody outside the company and the FDA can yet see is how often the data was right.

// How we reported this

Researched and drafted with AI tools, fact-checked against primary sources and approved by a human editor before publishing. Prices and dates are as of publication. Our standards →

Sources
  1. dreamed.ai — announced
  2. clinicaltrials.gov — ClinicalTrials.gov
  3. fda.gov — clinical decision support software
  4. cov.com — Covington
  5. fdanews.com — DreaMed's insulin dosing software earns clearances
  6. fdanews.com — DreaMed gets additional FDA clearance for diabetes analyzer
Columnist, Creator Economy & Culture Casie Stewart

Casie Stewart covers the creator economy, social platforms and wellness tech for prompt/power: who gets paid, who gets seen, and what the algorithm is really asking of the people who feed it. She has been publishing online since 2005, long before "creator" was a job title, and has spent most of that time on the other side of the platforms she now writes about. Based in Toronto. Her rule for any new app: if it promises to save you time, check how much of it you just spent reading the onboarding.

All stories by Casie →

Latest from prompt/power

  1. Broadcom’s AI chip sales now outstrip its entire business from a year ago. What to watch on Dec. 9Nov 19
  2. NeurIPS 2026 is in three cities. Here’s how the split worksNov 19
  3. Pay yearly or monthly? What you save on AI subscriptions in CanadaNov 19
  4. IBM, NVIDIA and Fermilab plan a quantum test bed. Here’s what each brings, and what’s still missingNov 19
  5. GPT-6.2 Astra is OpenAI’s first released model rated ‘High’ for AI self-improvement. What that means, and what it costsNov 18

Leave a Reply

Your email address will not be published. Required fields are marked *